With the start of the draft less than one week away, little movement is expected as it pertains to free agency. Dalton Risner ...

Image via Shutterstock Are you planning on going on a cruise ship soon? Then you should know about a new scam targeting ...

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other ...

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a ...

Châtillon, France, April 11, 2025 DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 ...

Shares of DBV Technologies (DBVT) are moving lower after the company a “substantial doubt regarding its ability to continue as a going concern.” When reporting unaudited results for 2024 ...

American depositary receipts of DBV Technologies gained after the company reported new financing of up to $306.9 million. The biopharmaceutical company's ADRs were up 57%, at $6.14, Friday morning.

It’s been more than three years since DBV Technologies’ peanuty allergy therapy was rejected for FDA approval, but the company thinks it now has a clear route to market with its patch product ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...